Your browser doesn't support javascript.
loading
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
Douillard, J-Y; Ostoros, G; Cobo, M; Ciuleanu, T; McCormack, R; Webster, A; Milenkova, T.
Afiliação
  • Douillard JY; Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Bd J. Monod, 44805 St-Herblain, Nantes, France.
  • Ostoros G; National Koranyi Institute of Pulmonology, Piheno ut 1, Budapest H-1121, Hungary.
  • Cobo M; Hospital Regional Universitario Carlos Haya, Málaga, Andalucia 29010, Spain.
  • Ciuleanu T; Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca 400015, Romania.
  • McCormack R; AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
  • Webster A; AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
  • Milenkova T; AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
Br J Cancer ; 110(1): 55-62, 2014 Jan 07.
Article em En | MEDLINE | ID: mdl-24263064
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article